Abdissa, SG, Fekade, D, Feleke, Y, Seboxa, T, and Diro, E (2012). Adverse drug reactions associated with antiretroviral treatment among adult Ethiopian patients in a tertiary hospital. Ethiop Med J 50(2): 107–113.
Ahmed, S, Zhou, Z, Zhou, J, and Chen, SQ (2016). Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Genomics Proteomics Bioinformatics 14(5): 298–313.
Akinboro, AO, Akinyemi, SO, Olaitan, PB, et al. (2014). Quality of life of Nigerians living with human immunodeficiency virus. Pan Afr Med J 18: 234.
Aklillu, E, Herrlin, K, Gustafsson, LL, Bertilsson, L, and Ingelman-Sundberg, M (2002). Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics 12(5): 375–383.
Anderson, T, Nkhoma, S, Ecker, A, and Fidock, D (2011). How can we identify parasite genes that underlie antimalarial drug resistance? Pharmacogenomics 12(1): 59–85.
Aneni, EC, Hamer, DH, and Gill, CJ (2013). Systematic review of current and emerging strategies for reducing morbidity from malaria in sickle cell disease. Trop Med Int Health 18: 313–327.
Angamo, MT, Curtain, CM, Chalmers, L, Yilma, D, and Bereznicki, L (2017). Predictors of adverse drug reaction-related hospitalization in Southwest Ethiopia: a prospective cross-sectional study. PLoS One 12(10): e0186631.
Ankathil, R (2017). ABCB1 genetic variants in leukemias: current insights into treatment outcomes. Pharmgenomics Pers Med 10: 169–181.
Apinjoh, TO, Mugri, RN, Miotto, O, et al. (2017). Molecular markers for artemisinin and partner drug resistance in natural Plasmodium falciparum populations following increased insecticide treated net coverage along the slope of mount Cameroon: cross-sectional study. Infect Dis Poverty 6(1): 136.
Arts, EJ and Hazuda, DJ (2012). HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2: a007161.
Atun, R, Davies, JI, Gale, EAM, et al. (2017). Diabetes in sub-Saharan Africa: from clinical care to health policy. Lancet Diabetes Endocrinol 5(8): 622–667.
Azuma, J, Ohno, M, Kubota, R, et al. (2013). Pharmacogenetics-based tuberculosis therapy research group. NAT2 genotype guided regimen reduces isoniazid induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol 69(5): 1091–1101.
Bader, LA and Elewa, H (2016). The impact of genetic and non-genetic factors on warfarin dose prediction in MENA region: a systematic review. PLoS One 11(12): e0168732.
Bains, RK, Kovacevic, M, Plaster, CA, et al. (2013). Molecular diversity and population structure at the Cytochrome P450 3A5 gene in Africa. BMC Genet 14: 34.
Baker, JL, Shriner, D, Bentley, AR, and Rotimi, CN (2017). Pharmacogenomic implications of the evolutionary history of infectious diseases in Africa. Pharmacogenomics J 17(2): 112–120.
Bapiro, TE, Hasler, JA, Ridderstrom, M, and Masimirembwa, CM (2002). The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant: potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations. Biochem Pharmacol 64: 1387–1398.
Becker, ML, Visser, LE, Van Schaik, RH, et al. (2009). Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 58: 745–749.
Beutler, E, Dern, RJ, and Alving, AS (1955). The hemolytic effect of primaquine: VI. An in vitro test for sensitivity of erythrocytes to primaquine. J Lab Clin Med 45: 40–50.
Bretscher, MT, Griffin, JT, Ghani, AC, and Okell, LC (2017). Modelling the benefits of long-acting or transmission-blocking drugs for reducing Plasmodium falciparum transmission by case management or by mass treatment. Malar J 16(1): 341.
Bringolf, L, Pestalozzi, B, Fink, D, and Dedes, K (2017). Exploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital. Swiss Med Wkly 146: w14393.
Brousseau, DC, Mccarver, DG, Drendel, AL, Divakaran, K, and Panepinto, JA (2007). The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis. J Pediatr 150: 623–626.
Byakika-Kibwika, P, Lamorde, M, Mayito, J, et al. (2012). Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother 67: 2213–2221.
Canestaro, WJ, Brooks, DG, Chaplin, D, et al. (2012). Statin pharmacogenomics: opportunities to improve patient outcomes and healthcare costs with genetic testing. J Pers Med 2: 158–174.
Carr, DF, Chaponda, M, Cornejo Castro, EM, et al. (2014). CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations. J Antimicrob Chemother 69: 3329–3334.
Carr, DF, Bourgeois, S, Chaponda, M, et al. (2017). Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population. J Antimicrob Chemother 72(4): 1152–1162.
Caudle, KE, Klein, TE, Hoffman, JM, et al. (2014). Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab 15(2): 209–217.
Chandra, R (2017). The role of pharmacogenomics in precision medicine. Med Lab Obs 49(9): 8–14.
Charache, S, Terrin, ML, Moore, RD, et al. (1995). Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia: investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 332: 1317–1322.
Chigutsa, E, Visser, ME, Swart, EC, et al. (2011). The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother 55(9): 4122–4127.
Choudhury, A, Ramsay, M, Hazelhurst, S, et al. (2017). Whole-genome sequencing for an enhanced understanding of genetic variation among South Africans. Nat Commun 8(1): 2062.
Collins, SL, Carr, DF, Pirmohamed, M (2016). Advances in the pharmacogenomics of adverse drug reactions. Drug Saf 39(1): 15–27.
Conrad, MD, Mota, D, Musiime, A, et al. (2017). Comparative prevalence of Plasmodium falciparum resistance-associated genetic polymorphisms in parasites infecting humans and mosquitoes in Uganda. Am J Trop Med Hyg 97(5): 1576–1580.
Crews, KR, Gaedigk, A, Dunnenberger, HM, et al. (2014). Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther 95(4): 376–382.
Crews, KR, Caudle, KE, Dunnenberger, HM, Sadhasivam, S, and Skaar, TC (2015). Considerations for the utility of the CPIC guideline for CYP2D6 genotype and codeine therapy. Clin Chem 61(5): 775–776.
Daka, A, Dimovski, A, Kapedanovska, A, et al. (2015). Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers. Pharmazie 70(7): 480–488.
Dandara, C, Basvi, PT, Bapiro, TE, Sayi, J, and Hasler, JA (2004). Frequency of -163 C>A and 63 C>G single nucleotide polymorphism of cytochrome P450 1A2 in two African populations. Clin Chem Lab Med 42: 939–941.
Dandara, C, Lombard, Z, Du Plooy, I, et al. (2011). Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity. Pharmacogenomics 12(12): 1663–1670.
Dandara, C, Swart, M, Mpeta, B, Wonkam, A, and Masimirembwa, C (2014). Cytochrome P450 pharmacogenetics in African populations: implications for public health. Expert Opin Drug Metab Toxicol 10: 769–785.
Dandara, C, Suarez-Kurtz, G, and Aklillu, E (2016). Conference report: first Pharmacogenetics and Precision Medicine Conference in Africa (April 7–9, 2016, Cape Town, South Africa). OMICS 20(9): 496–497.
Daneshjou, R, Gamazon, ER, Burkley, B, et al. (2014). Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans. Blood 124(14): 2298–2305.
Dang, MT, Hambleton, J, and Kayser, SR (2005). The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother 39: 1008–1012.
Darbari, DS, Minniti, CP, Rana, S, and Van Den Anker, J (2008a). Pharmacogenetics of morphine: potential implications in sickle cell disease. Am J Hematol 83: 233–236.
Darbari, DS, Van Schaik, RH, Capparelli, EV, et al. (2008b). UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am J Hematol 83: 200–202.
den Dunnen, JT, Dalgleish, R, Maglott, DR, et al. (2016). HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat 37(6): 564–569.
Deng, J, Vozmediano, V, Rodriguez, M, Cavallari, LH, and Schmidt, S (2017). Genotype-guided dosing of warfarin through modeling and simulation. Eur J Pharm Sci 109S: S9–S14.
Dhoro, M, Zvada, S, Ngara, B, et al. (2015). CYP2B6*6, CYP2B6*18, body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe. BMC Pharmacol Toxicol 27(16): 4.
Diop, S, Soudre, F, Seck, M, et al. (2011). Sickle-cell disease and malaria: evaluation of seasonal intermittent preventive treatment with sulfadoxine-pyrimethamine in Senegalese patients: a randomized placebo-controlled trial. Ann Hematol 90: 23–27.
Dooley, KE, Flexner, C, and Andrade, AS (2008). Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries. J Infect Dis 198: 948–961.
Dujic, T, Zhou, K, Donnelly, LA, et al. (2015). Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS study. Diabetes 64: 1786–1793.
Dujic, T, Zhou, K, Donnelly, LA, et al. (2018). Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea-induced hypoglycaemia: a GoDARTS study. Diabetes Obes Metab 20(1): 211–214.
Eke, FU and Anochie, I (2003). Effects of pyrimethamine versus proguanil in malarial chemoprophylaxis in children with sickle cell disease: a randomized, placebo-controlled, open-label study. Curr Ther Res Clin Exp 64: 616–625.
Eluwa, GI, Badru, T, Agu, KA, et al. (2012). Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria. BMC Clin Pharmacol 12: 7.
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group (2013). Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? Genet Med 15(7): 517–527.
Floyd, JS and Psaty, BM (2016). The application of genomics in diabetes: barriers to discovery and implementation. Diabetes Care 39(11): 1858–1869.
Fohner, A, Muzquiz, LI, Austin, MA, et al. (2013). Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes. Pharmacogenet Genomics 23: 403–414.
Fricke-Galindo, I, Céspedes-Garro, C, Rodrigues-Soares, F, et al. (2016). Interethnic variation of CYP2C19 alleles, “predicted” phenotypes and “measured” metabolic phenotypes across world populations. Pharmacogenomics J 16(2): 113–123.
Gaedigk, A, Blum, M, Gaedigk, R, Eichelbaum, M, and Meyer, UA (1991). Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 48(5): 943–950.
Gaedigk, A, Simon, SD, Pearce, RE, et al. (2008). The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83: 234–242.
Gaedigk, A, Ingelman-Sundberg, M, Miller, NA, et al. (2017a). The Pharmacogene Variation (PharmVar) Consortium: incorporation of the human cytochrome P450 (CYP) allele nomenclature database. Clin Pharmacol Ther. DOI: 10.1002/cpt.910.
Gaedigk, A, Sangkuhl, K, Whirl-Carrillo, M, Klein, T, and Leeder, JS (2017b). Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med 19(1): 69–76.
Ganesh, SK, Arnett, DK, Assimes, TL, et al. (2013). Genetics and genomics for the prevention and treatment of cardiovascular disease: update – a scientific statement from the American Heart Association. Circulation 128: 2813–2851.
Gelissen, IC and Brown, AJ (2012). Predicting response to statins by pharmacogenetic testing. Pharmacogenomics 13: 1223–1225.
Gounden, V, Van Niekerk, C, Snyman, T, and George, JA (2010). Presence of the CYP2B6 516G> T polymorphism, increased plasma efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res Ther 7: 32.
Green, NS and Barral, S (2011). Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease. Pediatr Blood Cancer 56: 177–181.
Grosse, SD, Odame, I, Atrash, HK, et al. (2011). Sickle cell disease in Africa: a neglected cause of early childhood mortality. Am J Prev Med 41: S398–S405.
Guo, Y, Shi, L, Hong, H, et al. (2013). Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine. Sci China Life Sci 56(2): 119–124.
Gupta, VH, Amarapurkar, DN, Singh, M, et al. (2013). Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India. J Gastroenterol Hepatol 28: 1368–1374.
Gurdasani, D, Carstensen, T, Tekola-Ayele, F, et al. (2015). The African Genome Variation Project shapes medical genetics in Africa. Nature 517(7534): 327–332.
Hansen, NT, Brunak, S, and Altman, RB (2009). Generating genome-scale candidate gene lists for pharmacogenomics. Clin Pharmacol Ther 86: 183–189.
He, L, Vasiliou, K and Nebert, DW (2009). Analysis and update of the human solute carrier (SLC) gene superfamily. Hum Genomics 3(2): 195–206.
Helland, T, Henne, N, Bifulco, E, et al. (2017). Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients. Breast Cancer Res 19(1): 125.
Hennig, S, Naiker, S, Reddy, T, et al. (2015). Effect of SLCO1B1 polymorphisms on rifabutin pharmacokinetics in African HIV-infected patients with tuberculosis. Antimicrob Agents Chemother 60(1): 617–620.
Hicks, JK, Swen, JJ, Thorn, CF, et al. (2013). Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 93: 402–408.
Holstein, A, Hahn, M, Korner, A, Stumvoll, M, and Kovacs, P (2011). TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes. BMC Med Genet 12: 30.
Howes, RE, Piel, FB, Patil, AP, et al. (2012). G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med 9(11): e1001339.
Hu, M and Tomlinson, B (2013). Pharmacogenomics of lipid-lowering therapies. Pharmacogenomics 14: 981–995.
Jaffar, S and Gill, G (2017). The crisis of diabetes in sub-Saharan Africa. Lancet Diabetes Endocrinol 5(8): 574–575.
Johansson, I and Ingelman-Sundberg, M (2008). Current research in drug metabolism, drug transport and drug development. Drug News Perspect 21(9): 518–528.
Joly, P, Gagnieu, MC, Bardel, C, et al. (2012). Genotypic screening of the main opiate-related polymorphisms in a cohort of 139 sickle cell disease patients. Am J Hematol 87: 534–536.
Jung, JA, Kim, TE, Lee, H, et al. (2015). A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis. Drug Des Devel Ther 9: 5433–5438. DOI: 10.2147/DDDT.S87131.
Kalman, LV, Agúndez, J, Appell, ML, et al. (2016). Pharmacogenetic allele nomenclature: international workgroup recommendations for test result reporting. Clin Pharmacol Ther 99(2): 172–185. DOI: 10.1002/cpt.280.
Kalow, W (1956). Familial incidence of low pseudocholinesterase level. Lancet 268: 576–577.
Kaye, JB, Schultz, LE, Steiner, HE, et al. (2017). Warfarin pharmacogenomics in diverse populations. Pharmacotherapy 37(9): 1150–1163.
Kharsany, AB and Karim, QA (2016). HIV infection and AIDS in sub-Saharan Africa: current status, challenges and opportunities. Open AIDS J 10: 34–48.
Kitzmiller, JP, Groen, DK, Phelps, MA, and Sadee, W (2011). Pharmacogenomic testing: relevance in medical practice – why drugs work in some patients but not in others. Cleve Clin J Med 78: 243–257.
Klein, K, Lang, T, Saussele, T, et al. (2005). Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 15(12): 861–873.
Kubo, K, Ohara, M, Tachikawa, M, et al. (2017). Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms. Pharmacogenomics J 17(6): 494–500.
Kudzi, W, Addy, BS, and Dzudzor, B (2015). Knowledge of pharmacogenetics among healthcare professionals and faculty members of health training institutions in Ghana. Ghana Med J 49(1): 50–56.
Lee, J, Wang, R, Yang, Y, et al. (2015). The effect of ABCB1 C3435T polymorphism on cyclosporine dose requirements in kidney transplant recipients: a meta-analysis. Basic Clin Pharmacol Toxicol 117(2): 117–125.
Lettre, G, Sankaran, VG, Bezerra, MA, et al. (2008). DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. PNAS 105: 11869–11874.
Lewthwaite, CJ (1962). A trial of chemoprophylaxis in sickle cell anaemia: preliminary communication. East Afr Med J 39: 196–199.
Li, J, Lao, X, Zhang, C, et al. (2014). Increased genetic diversity of ADME genes in African Americans compared with their putative ancestral source populations and implications for pharmacogenomics. BMC Genet 15: 52.
Li, Q, Tang, TT, Jiang, F, et al. (2017). Polymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes. Acta Pharmacol Sin 38(1): 80–89.
Limdi, NA, Brown, TM, Yan, Q, et al. (2015). Race influences warfarin dose changes associated with genetic factors. Blood 126(4): 539–545.
Lynch, T and Price, A (2007). The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 76(3): 391–396.
Maimbo, M, Kiyotani, K, Mushiroda, T, Masimirembwa, C, and Nakamura, Y (2012). CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans. Eur J Clin Pharmacol 68: 267–271.
Makani, J, Komba, AN, Cox, SE, et al. (2010). Malaria in patients with sickle cell anemia: burden, risk factors, and outcome at the outpatient clinic and during hospitalization. Blood 115: 215–220.
Makani, J, Ofori-Acquah, SF, Nnodu, O, Wonkam, A, and Ohene-Frempong, K (2013). Sickle cell disease: new opportunities and challenges in Africa. Sci World J 2013: 193252.
Malik, VS, Popkin, BM, Bray, GA, Despres, JP, and Hu, FB (2010). Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk. Circulation 121: 1356–1364.
Manjurano, A, Sepulveda, N, Nadjm, B, et al. (2015). African glucose-6-phosphate dehydrogenase alleles associated with protection from severe malaria in heterozygous females in Tanzania. PLoS Genet 11(2): e1004960.
Masenyetse, LJ, Manda, SO, and Mwambi, HG (2015). An assessment of adverse drug reactions among HIV positive patients receiving antiretroviral treatment in South Africa. AIDS Res Ther 12: 6.
Masimirembwa, C and Matimba, A (2012). Pharmacogenomics in Africa: diversity as an opportunity for personalized healthcare in genomics applications for the developing world. In Nelson, KE and Jones-Nelson, B, eds., Genomics Applications for the Developing World. Springer, pp. 161–181.
Masimirembwa, C, Persson, I, Bertilsson, L, Hasler, J, and Ingelman-Sundberg, M (1996). A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 42: 713–719.
Masimirembwa, C, Dandara, C, and Hasler, J (2014). Population diversity and pharmacogenomics in Africa. In Padmanabhan, S., ed., Handbook of Pharmacogenomics and Stratified Medicine. Academic Press, pp. 161–182.
Masimirembwa, C, Dandara, C, and Leutscher, PD (2016). Rolling out efavirenz for HIV precision medicine in Africa: are we ready for pharmacovigilance and tackling neuropsychiatric adverse effects? OMICS 20(10): 575–580.
Matimba, A, Oluka, MN, Ebeshi, BU, et al. (2008). Establishment of a biobank and pharmacogenetics database of African populations. Eur J Hum Genet 16(7): 780–783.
Matimba, A, Del-Favero, J, Van Broeckhoven, C, and Masimirembwa, C (2009). Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. Hum Genomics 3(2): 169–190.
Matimba, A, Dhoro, M, and Dandara, C (2016). Is there a role of pharmacogenomics in Africa? Glob Health Epidemiol Genom 1. DOI: 10.1017/gheg.2016.4.
Maxwell, RR and Cole, PD (2017). Pharmacogenetic predictors of treatment-related toxicity among children with acute lymphoblastic leukemia. Curr Hematol Malig Rep 12(3): 176–186.
McAuley, CF, Webb, C, Makani, J, et al. (2010). High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya. Blood 116: 1663–1668.
Meyer, ZU, Schwabedissen, HE, Albers, M, et al. (2015). Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort. Pharmacogenet Genomics 25(1): 8–18.
Mhandire, D, Lacerda, M, Castel, S, et al. (2015). Effects of CYP2B6 and CYP1A2 genetic variation on nevirapine plasma concentration and pharmacodynamics as measured by CD4 cell count in Zimbabwean HIV-infected patients. OMICS 19(9): 553–562.
Mitchell, C, Gregersen, N, and Krause, A (2011). Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics 12: 953–963.
Moaddeb, J and Haga, SB (2013). Pharmacogenetic testing: current evidence of clinical utility. Ther Adv Drug Saf 4(4): 155–169.
Modell, B and Darlison, M (2008). Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 86: 480–487.
Moriyama, T, Yang, YL, Nishii, R, et al. (2017). Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry. Blood 130(10): 1209–1212.
Moss, DM, Liptrott, NJ, Siccardi, M, and Owen, A (2015). Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter. Front Pharmacol 6: 78.
Moss, JA (2013). HIV/AIDS review. Radiol Technol 84(3): 247–267.
Mouton, JP, Njuguna, C, Kramer, N, et al. (2016). Adverse drug reactions causing admission to medical wards: a cross-sectional survey at 4 hospitals in South Africa. Medicine (Baltimore) 95(19): e3437.
Mpye, K, Matimba, A, Dzobo, K, et al. (2016). Disease burden and the role of pharmacogenomics in African populations. Glob Health Epidemiol Genom 2. DOI: 10.1017/gheg.2016.21.
Mtatiro, SN, Singh, T, Rooks, H, et al. (2014). Genome wide association study of fetal hemoglobin in sickle cell anemia in Tanzania. PLoS One 9: e111464.
Mtatiro, SN, Mgaya, J, Singh, T, et al. (2015). Genetic association of fetal-hemoglobin levels in individuals with sickle cell disease in Tanzania maps to conserved regulatory elements within the MYB core enhancer. BMC Med Genet 16: 4.
Mukonzo, JK, Okwera, A, Nakasujja, N, et al. (2013). Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. BMC Infect Dis 13: 261.
Mukonzo, JK, Owen, JS, Ogwal-Okeng, J, et al. (2014). Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes. PLoS One 9(1): e86919.
Mutabazi-Mwesigire, D, Seeley, J, Martin, F, and Katamba, A (2014). Perceptions of quality of life among Ugandan patients living with HIV: a qualitative study. BMC Public Health 10(14): 343.
Namme Luma, H, Doualla, MS, Choukem, SP, et al. (2012). Adverse drug reactions of highly active antiretroviral therapy (HAART) in HIV infected patients at the General Hospital, Douala, Cameroon: a cross sectional study. Pan Afr Med J 12: 87.
Ndefo, UA, Maxwell, AE, Nguyen, H, and Chiobi, TL (2008). Pharmacological management of sickle cell disease. Pharm Ther 33: 238–243.
Ngaimisi, E, Habtewold, A, Minzi, O, et al. (2013). Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. PLoS One 8: e67946.
Nyakutira, C, Roshammar, D, Chigutsa, E, et al. (2008). High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 64: 357–365.
Nyirenda, MJ (2016). Non-communicable diseases in sub-Saharan Africa: understanding the drivers of the epidemic to inform intervention strategies. Int Health 8(3): 157–158.
Okwi, AL, Byarugaba, W, Ndugwa, CM, et al. (2010). An up-date on the prevalence of sickle cell trait in Eastern and Western Uganda. BMC Blood Disord 10: 5.
Oluka, MN, Okalebo, FA, Guantai, AN, Mcclelland, RS, and Graham, SM (2015). Cytochrome P450 2B6 genetic variants are associated with plasma nevirapine levels and clinical response in HIV-1 infected Kenyan women: a prospective cohort study. AIDS Res Ther 12: 10.
Ombeni, W and Kamuhabwa, AR (2016). Lipid profile in HIV-infected patients using first-line antiretroviral drugs. J Int Assoc Provid AIDS Care 15(2): 164–171.
Oniyangi, O and Omari, AA (2006). Malaria chemoprophylaxis in sickle cell disease. Cochrane Database Syst Rev 4: Cd003489.
Perera, MA, Cavallari, LH, Limdi, NA, et al. (2013). Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet 382(9894): 790–796.
Pino, P, Taoufiq, Z, Brun, M, et al. (2006). Effects of hydroxyurea on malaria, parasite growth and adhesion in experimental models. Parasite Immunol 28: 675–680.
Pirmohamed, M, Burnside, G, Eriksson, N, et al. (2013). A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 369(24): 2294–2303.
Preissner, SC, Hoffmann, MF, Preissner, R, et al. (2013). Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS One 8(12): e82562.
Price-Evans, DA, Manley, FA, and Mckusick, VA (1960). Genetic control of isoniazid metabolism in man. Br Med J 2: 485–491.
Rajman, I, Knapp, L, Morgan, T, and Masimirembwa, C (2017). African genetic diversity: implications for Cytochrome P450 mediated drug metabolism and drug development. EBioMedicine 17: 67–74.
Rasmussen, SA, Ceja, FG, Conrad, MD, et al. (2017). Changing antimalarial drug sensitivities in Uganda. Antimicrob Agents Chemother 61(12): e01516-17.
Relling, MV and Klein, TE (2011). CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 89(3): 464–467.
Relling, MV, Gardner, EE, Sandborn, WJ, et al. (2013). Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther. 93: 324–325.
Rendic, S and Guengerich, FP (2010). Update information on drug metabolism systems: 2009, part II – summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters. Curr Drug Metab 11(1): 4–84.
Robarge, JD, Li, L, Desta, Z, Nguyen, A, and Flockhart, DA (2007). The star-allele nomenclature: retooling for translational genomics. Clin Pharmacol Ther 82(3): 244–248.
Roden, DM, Wilke, RA, Kroemer, HK, and Stein, CM (2011). Pharmacogenomics: the genetics of variable drug responses. Circulation 123(15): 1661–1670.
Röhrich, CR, Drögemöller, BI, Ikediobi, O, et al. (2016). CYP2B6*6 and CYP2B6*18 predict long-term efavirenz: exposure measured in hair samples in HIV-positive South African women. AIDS Res Hum Retroviruses 32(6): 529–538.
Ruiz-Iruela, C, Padullés-Zamora, N, Podzamczer-Palter, D, et al. (2016). HLA-B*57:01 genotyping in the prevention of hypersensitivity to abacavir: 5 years of experience. Pharmacogenet Genomics 26(8): 390–396.
Saladores, P, Mürdter, T, Eccles, D, et al. (2015). Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenomics J 15(1): 84–94.
Sarfo, FS, Zhang, Y, Egan, D, et al. (2014). Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. J Antimicrob Chemother 69(2): 491–499.
Schelleman, H, Chen, J, Chen, Z, et al. (2008). Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther 84: 332–339.
Schmidt, KT, Chau, CH, Price, DK, and Figg, WD (2016). Precision oncology medicine: the clinical relevance of patient-specific biomarkers used to optimize cancer treatment. J Clin Pharmacol 56(12): 1484–1499.
Shah, SS, Rockett, KA, Jallow, M, et al. (2016). Heterogeneous alleles comprising G6PD deficiency trait in West Africa exert contrasting effects on two major clinical presentations of severe malaria. Malar J 15: 13.
Shekalaghe, SA, Ter Braak, R, Daou, M, et al. (2010). In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals. Antimicrob Agents Chemother 54(5): 1762–1768.
Shi, C, Yan, W, Wang, G, et al. (2015). Pharmacogenetics-based versus conventional dosing of warfarin: a meta-analysis of randomized controlled trials. PLoS One 10(12): e0144511.
Shord, SS, Cavallari, LH, Gao, W, et al. (2009). The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease. Eur J Clin Pharmacol 65: 651–658.
Small, CB, Margolis, DA, Shaefer, MS, and Ross, LL (2017). HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects. BMC Infect Dis 17(1): 256.
Soko, ND, Masimirembwa, C, and Dandara, C (2016). Pharmacogenomics of rosuvastatin: a glocal (global+local) African perspective and expert review on a statin drug. OMICS 20(9): 498–509.
Sun, Q, Liu, HP, Zheng, RJ, et al. (2017). Genetic polymorphisms of SLCO1B1, CYP2E1 and UGT1A1 and susceptibility to anti-tuberculosis drug-induced hepatotoxicity: a Chinese population-based prospective case–control study. Clin Drug Investig 37(12): 1125–1136.
Sundelin, E, Gormsen, LC, Jensen, JB, et al. (2017). Genetic polymorphisms in organic cation transporter 1 attenuates hepatic metformin exposure in humans. Clin Pharmacol Ther 102(5): 841–848.
Swart, M, Ren, Y, Smith, P, and Dandara, C (2012a). ABCB1 4036A>G and 1236C>T polymorphisms affect plasma efavirenz levels in South African HIV/AIDS patients. Front Genet 3: 236.
Swart, M, Whitehorn, H, Ren, Y, et al. (2012b). PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients. BMC Med Genet 13: 112.
Swart, M, Skelton, M, Ren, Y, et al. (2013). High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients. Pharmacogenet Genomics 23: 415–427.
Swen, JJ, Nijenhuis, M, De Boer, A, et al. (2011). Pharmacogenetics: from bench to byte – an update of guidelines. Clin Pharmacol Ther 89: 662–673.
Takeuchi, F, Mcginnis, R, Bourgeois, S, et al. (2009). A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 5(3): e1000433.
Tang, T, Liu, J, Zuo, K, et al. (2015). Genotype-guided dosing of coumarin anticoagulants: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther 20(4): 387–394.
Thein, SL and Menzel, S (2009). Discovering the genetics underlying foetal haemoglobin production in adults. Br J Haematol 145: 455–467.
Thomford, N, Dzobo, K, Chopera, D, et al. (2015). Pharmacogenomics implications of using herbal medicinal plants on African populations in health transition. Pharmaceuticals 8: 637.
Thorn, CF, Klein, TE, and Altman, RB (2013). PharmGKB: the Pharmacogenomics Knowledge Base. Methods Mol Biol 1015: 311–320.
Toure, MC, Niang, A, Diop, C, et al. (2016). Prevention of isoniazid toxicity by NAT2 genotyping in Senegalese tuberculosis patients. Toxicol Rep 3: 826–831.
Twist, GP, Gaedigk, A, Miller, NA, et al. (2016). Constellation: a tool for rapid, automated phenotype assignment of a highly polymorphic pharmacogene, CYP2D6, from whole-genome sequences. NPJ Genom Med 1: 15007.
Vasiliou, V, Vasiliou, K, and Nebert, DW (2009). Human ATP-binding cassette (ABC) transporter family. Hum Genomics 3(3): 281–290.
Vo, TT and Varghese Gupta, S (2016). Role of Cytochrome P450 2B6 pharmacogenomics in determining efavirenz-mediated central nervous system toxicity, treatment outcomes, and dosage adjustments in patients with human immunodeficiency virus infection. Pharmacotherapy 36(12): 1245–1254.
Von Seidlein, L, Auburn, S, Espino, F, et al. (2013). Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report. Malar J 12: 112.
Wadelius, M (2014). Warfarin pharmacogenetics: it matters if you’re black or white. Blood 124(14): 2171.
Wang, P, Pradhan, K, Zhong, XB, and Ma, X (2016). Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B 6(5): 384–392.
Ward, BA, Gorski, JC, Jones, DR, et al. (2003). The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306(1): 287–300.
Ware, RE, Eggleston, B, Redding-Lallinger, R, et al. (2002). Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood 99: 10–14.
Ware, RE, Despotovic, JM, Mortier, NA, et al. (2011). Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood 118: 4985–4991.
Watson, J, Taylor, WR, Menard, D, Kheng, S, and White, NJ (2017). Modelling primaquine-induced haemolysis in G6PD deficiency. Elife 6: e23061.
Weiner, M, Peloquin, C, Burman, W, et al. (2010). Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother 54(10): 4192–4200.
Weinshilboum, RM and Wang, L (2017). Pharmacogenomics: precision medicine and drug response. Mayo Clin Proc 92(11): 1711–1722.
Wennerholm, A, Johansson, I, Hidestrand, M, et al. (2001). Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. Pharmacogenetics 11: 417–427.
Wennerholm, A, Dandara, C, Sayi, J, et al. (2002). The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. Clin Pharmacol Ther 71: 77–88.
WHO (2016). Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach, 2nd edn. Available at: www.who.int/hiv/pub/arv/chapter4.pdf?ua=1 (accessed January 2, 2017).
Wonkam, A (2017). Is there a role for pharmacogenetics in the treatment of sickle cell disease? Pharmacogenomics 18(4): 321–325.
Wonkam, A, Ngo Bitoungui, VJ, Vorster, AA, et al. (2014). Association of variants at BCL11A and HBS1L-MYB with hemoglobin F and hospitalization rates among sickle cell patients in Cameroon. PLoS One 9: e92506.
Wright, GE, Niehaus, DJ, Drogemoller, BI, et al. (2010). Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population. Ann Hum Genet 74: 340–350.
Yang, JJ and Bhojwani, D (2013). Thiopurine S-methyltransferase pharmacogenetics in childhood acute lymphoblastic leukemia. Methods Mol Biol 999: 273–284.
Yang, JJ, Landier, W, Yang, W, et al. (2015). Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol 33(11): 1235–1242.
Yee, MM, Josephson, C, Hill, CE, et al. (2013). Cytochrome P450 2D6 polymorphisms and predicted opioid metabolism in African American children with sickle cell disease. J Pediatr Hematol Oncol 35: e301–e305.
Zanger, UM and Klein, K (2013). Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet 4: 24.
Zanger, UM and Schwab, M (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138(1): 103–141.
Zembutsu, H (2015). Pharmacogenomics toward personalized tamoxifen therapy for breast cancer. Pharmacogenomics 16: 287–296.
Zhou, K, Donnelly, L, Burch, L, et al. (2010). Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Clin Pharmacol Ther 87(1): 52–56.